NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target

Frontiers in Bioscience

Volumn 16, Issue 3, 2011, Pages 1172-1185

  Chen, Wenshu ^a   Li, Zi ^a   Bai, Lang ^a   Lin, Yong ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Lung cancer; NF kappaB; Prevention; Review; Signaling; Therapy

Indexed keywords

ANIMALIA; NICOTIANA TABACUM;

CARCINOGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEASOME;

ADENOCARCINOMA; ANIMAL; APOPTOSIS; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; CHEMOPROPHYLAXIS; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; INFLAMMATION; LUNG TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CARCINOGENS; CELL PROLIFERATION; CHEMOPREVENTION; HUMANS; INFLAMMATION; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION;

EID: 79955068704     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3782     Document Type: Article

References (130)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray and M. J. Thun: Cancer statistics, 2008. CA Cancer J Clin, 58(2), 71-96 (2008) (Pubitemid 351521864)
2. B. N. Ames and L. S. Gold: The causes and prevention of cancer: the role of environment. Biotherapy, 11(2-3), 205-20 (1998) (Pubitemid 28284933)
3. A. Onn, M. Tsuboi and N. Thatcher: Treatment of nonsmall- cell lung cancer: a perspective on the recent advances and the experience with gefitinib. Br J Cancer, 91 Suppl 2, S11-7 (2004) (Pubitemid 39331427)
4. D. Hanahan and R. A. Weinberg: The hallmarks of cancer. Cell, 100(1), 57-70 (2000) (Pubitemid 30046295)
5. M. S. Hayden and S. Ghosh: Signaling to NF-kappaB. Genes Dev, 18(18), 2195-224 (2004)
6. Y. Lin, L. Bai, W. Chen and S. Xu: The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets, 14(1), 45-55 (2010)
7. A. Devin, A. Cook, Y. Lin, Y. Rodriguez, M. Kelliher and Z. Liu: The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity, 12(4), 419-29 (2000)
8. J. Yang, Y. Lin, Z. Guo, J. Cheng, J. Huang, L. Deng, W. Liao, Z. Chen, Z. Liu and B. Su: The essential role of MEKK3 in TNF-induced NF-kappaB activation. Nat Immunol, 2(7), 620-4 (2001) (Pubitemid 32677629)
9. Z. J. Chen: Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol, 7(8), 758-65 (2005)
10. H. C. Thoms, C. J. Loveridge, J. Simpson, A. Clipson, K. Reinhardt, M. G. Dunlop and L. A. Stark: Nucleolar targeting of RelA(p65) is regulated by COMMD1- dependent ubiquitination. Cancer Res, 70(1), 139-49 (2010)
11. N. Festjens, T. Vanden Berghe, S. Cornelis and P. Vandenabeele: RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ, 14(3), 400-10 (2007)
12. C. J. Wu, D. B. Conze, T. Li, S. M. Srinivasula and J. D. Ashwell: NEMO is a sensor of Lys 63-linked polyubiquitination and functions in NF-kappaB activation. Nat Cell Biol, 8(4), 398-406 (2006)
13. F. Renner, R. Moreno and M. L. Schmitz: SUMOylation-Dependent Localization of IKKvarepsilon in PML Nuclear Bodies Is Essential for Protection against DNA-Damage-Triggered Cell Death. Mol Cell, 37(4), 503-515 (2010)
14. B. J. Zarnegar, Y. Wang, D. J. Mahoney, P. W. Dempsey, H. H. Cheung, J. He, T. Shiba, X. Yang, W. C. Yeh, T. W. Mak, R. G. Korneluk and G. Cheng: Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol, 9(12), 1371-8 (2008)
15. D. A. Barbie, P. Tamayo, J. S. Boehm, S. Y. Kim, S. E. Moody, I. F. Dunn, A. C. Schinzel, P. Sandy, E. Meylan, C. Scholl, S. Frohling, E. M. Chan, M. L. Sos, K. Michel, C. Mermel, S. J. Silver, B. A. Weir, J. H. Reiling, Q. Sheng, P. B. Gupta, R. C. Wadlow, H. Le, S. Hoersch, B. S. Wittner, S. Ramaswamy, D. M. Livingston, D. M. Sabatini, M. Meyerson, R. K. Thomas, E. S. Lander, J. P. Mesirov, D. E. Root, D. G. Gilliland, T. Jacks and W. C. Hahn: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature, 462(7269), 108-12 (2009)
16. T. Kato, Jr., M. Delhase, A. Hoffmann and M. Karin: CK2 Is a C-Terminal IkappaB Kinase Responsible for NFkappaB Activation during the UV Response. Mol Cell, 12(4), 829-39 (2003) (Pubitemid 37352777)
17. P. Viatour, M. P. Merville, V. Bours and A. Chariot: Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci, 30(1), 43-52 (2005) (Pubitemid 40093740)
18. W. Chen, X. Wang, L. Bai, X. Liang, J. Zhuang and Y. Lin: Blockage of NF-kappaB by IKKbeta- or RelA-siRNA rather than the NF-kappaB super-suppressor IkappaBalpha mutant potentiates adriamycin-induced cytotoxicity in lung cancer cells. J Cell Biochem, 105(2), 554-61 (2008)
19. G. M. Hur, J. Lewis, Q. Yang, Y. Lin, H. Nakano, S. Nedospasov and Z. G. Liu: The death domain kinase RIP has an essential role in DNA damage-induced NF-kappa B activation. Genes Dev, 17(7), 873-82 (2003) (Pubitemid 36397375)
20. K. J. Campbell, S. Rocha and N. D. Perkins: Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell, 13(6), 853-65 (2004) (Pubitemid 38438480)
21. S. Rocha, M. D. Garrett, K. J. Campbell, K. Schumm and N. D. Perkins: Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J, 24(6), 1157-69 (2005) (Pubitemid 40516599)
22. F. Chen, Y. Lu, Z. Zhang, V. Vallyathan, M. Ding, V. Castranova and X. Shi: Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J Biol Chem, 276(14), 11414-9 (2001) (Pubitemid 38089335)
23. M. Karin: The IkappaB kinase - a bridge between inflammation and cancer. Cell Res, 18(3), 334-42 (2008) (Pubitemid 351333897)
24. M. Karin and A. Lin: NF-kappaB at the crossroads of life and death. Nat Immunol, 3(3), 221-7 (2002)
25. F. R. Greten, L. Eckmann, T. F. Greten, J. M. Park, Z. W. Li, L. J. Egan, M. F. Kagnoff and M. Karin: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118(3), 285-96 (2004) (Pubitemid 39061110)
26. W. Ju, X. Wang, H. Shi, W. Chen, S. A. Belinsky and Y. Lin: A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol, 71(5), 1381-8 (2007) (Pubitemid 46658691)
27. G. Tang, Y. Minemoto, B. Dibling, N. H. Purcell, Z. Li, M. Karin and A. Lin: Inhibition of JNK activation through NF-kappaB target genes. Nature, 414(6861), 313-7 (2001) (Pubitemid 33097808)
28. B. Kaltschmidt, C. Kaltschmidt, T. G. Hofmann, S. P. Hehner, W. Droge and M. L. Schmitz: The pro- or antiapoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus. Eur J Biochem, 267(12), 3828-35 (2000) (Pubitemid 30423046)
29. K. M. Kim and Y. J. Lee: Amiloride augments TRAILinduced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway. Oncogene, 24(3), 355-66 (2005) (Pubitemid 40188584)
30. J. Li, H. Jia, L. Xie, X. Wang, H. He, Y. Lin and L. Hu: Association of constitutive nuclear factor-kappaB activation with aggressive aspects and poor prognosis in cervical cancer. Int J Gynecol Cancer, 19(8), 1421-6 (2009)
31. M. Karin and F. R. Greten: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol, 5(10), 749-59 (2005) (Pubitemid 41400849)
32. X. Jin, Z. Wang, L. Qiu, D. Zhang, Z. Guo, Z. Gao, C. Deng, F. Wang, S. Wang and C. Guo: Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer. Cancer Sci, 99(3), 582-9 (2008) (Pubitemid 351228577)
33. X. Wang, W. Ju, J. Renouard, J. Aden, S. A. Belinsky and Y. Lin: 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factorkappaB pathway. Cancer Res, 66(2), 1089-95 (2006) (Pubitemid 43165977)
34. X. Wang, W. Chen and Y. Lin: Sensitization of TNFinduced cytotoxicity in lung cancer cells by concurrent suppression of the NF-kappaB and Akt pathways. Biochem Biophys Res Commun, 355(3), 807-12 (2007) (Pubitemid 46330225)
35. H. Takahashi, H. Ogata, R. Nishigaki, D. H. Broide and M. Karin: Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell, 17(1), 89-97 (2010)
36. D. S. Basseres, A. Ebbs, E. Levantini and A. S. Baldwin: Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res, 70(9), 3537-46 (2010)
37. E. Meylan, A. L. Dooley, D. M. Feldser, L. Shen, E. Turk, C. Ouyang and T. Jacks: Requirement for NFkappaB signalling in a mouse model of lung adenocarcinoma. Nature, 462(7269), 104-7 (2009)
38. C. J. Smith, T. A. Perfetti and J. A. King: Perspectives on pulmonary inflammation and lung cancer risk in cigarette smokers. Inhal Toxicol, 18(9), 667-77 (2006)
39. A. Emmendoerffer, M. Hecht, T. Boeker, M. Mueller and U. Heinrich: Role of inflammation in chemical-induced lung cancer. Toxicol Lett, 112-113, 185-91 (2000) (Pubitemid 30138122)
40. K. K. Wong, T. Jacks and G. Dranoff: NF-kappaB fans the flames of lung carcinogenesis. Cancer Prev Res (Phila Pa), 3(4), 403-5 (2010)
41. J. Tsurutani, S. S. Castillo, J. Brognard, C. A. Granville, C. Zhang, J. J. Gills, J. Sayyah and P. A. Dennis: Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis, 26(7), 1182-95 (2005) (Pubitemid 41417895)
42. S. Janssens and J. Tschopp: Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ, 13(5), 773-84 (2006)
43. J. A. Gustin, O. N. Ozes, H. Akca, R. Pincheira, L. D. Mayo, Q. Li, J. R. Guzman, C. K. Korgaonkar and D. B. Donner: Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. J Biol Chem, 279(3), 1615-20 (2004) (Pubitemid 38084426)
44. G. Chen, M. S. Bhojani, A. C. Heaford, D. C. Chang, B. Laxman, D. G. Thomas, L. B. Griffin, J. Yu, J. M. Coppola, T. J. Giordano, L. Lin, D. Adams, M. B. Orringer, B. D. Ross, D. G. Beer and A. Rehemtulla: Phosphorylated FADD induces NF-{kappa}B, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A, 102(35), 12507-12 (2005) (Pubitemid 41266389)
45. G. Sethi, K. S. Ahn, M. M. Chaturvedi and B. B. Aggarwal: Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinaseindependent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene, 26(52), 7324-32 (2007) (Pubitemid 350115978)
46. N. D. Perkins: NF-kappaB: tumor promoter or suppressor? Trends Cell Biol, 14(2), 64-9 (2004)
47. E. Pikarsky and Y. Ben-Neriah: NF-kappaB inhibition: a double-edged sword in cancer? Eur J Cancer, 42(6), 779-84 (2006)
48. G. T. Stathopoulos, T. P. Sherrill, D. S. Cheng, R. M. Scoggins, W. Han, V. V. Polosukhin, L. Connelly, F. E. Yull, B. Fingleton and T. S. Blackwell: Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A, 104(47), 18514-9 (2007)
49. J. Deng, J. Fujimoto, X. F. Ye, T. Y. Men, C. S. Van Pelt, Y. L. Chen, X. F. Lin, H. Kadara, Q. Tao, D. Lotan and R. Lotan: Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis. Cancer Prev Res (Phila Pa), 3(4), 424-37 (2010)
50. X. Wang and Y. Lin: Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin, 29(11), 1275-88 (2008)
51. S. I. Grivennikov, F. R. Greten and M. Karin: Immunity, inflammation, and cancer. Cell, 140(6), 883-99 (2010)
52. C. Y. Chu, S. T. Cha, W. C. Lin, P. H. Lu, C. T. Tan, C. C. Chang, B. R. Lin, S. H. Jee and M. L. Kuo: Stromal cell-derived factor-1alpha (SDF- 1alpha/CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1/2-NFkappaB/ interleukin-6 pathway. Carcinogenesis, 30(2), 205-13 (2009)
53. S. K. Raghuwanshi, M. W. Nasser, X. Chen, R. M. Strieter and R. M. Richardson: Depletion of betaarrestin- 2 promotes tumor growth and angiogenesis in a murine model of lung cancer. J Immunol, 180(8), 5699-706 (2008)
54. S. P. Tabruyn and A. W. Griffioen: Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun, 355(1), 1-5 (2007) (Pubitemid 46273381)
55. M. A. Huber, H. Beug and T. Wirth: Epithelialmesenchymal transition: NF-kappaB takes center stage. Cell Cycle, 3(12), 1477-80 (2004) (Pubitemid 40521393)
56. C. Y. Huang, Y. C. Fong, C. Y. Lee, M. Y. Chen, H. C. Tsai, H. C. Hsu and C. H. Tang: CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol, 77(5), 794-803 (2009)
57. C. H. Tang, T. W. Tan, W. M. Fu and R. S. Yang: Involvement of matrix metalloproteinase-9 in stromal cellderived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis, 29(1), 35-43 (2008)
58. J. Goffin, C. Lacchetti, P. M. Ellis, Y. C. Ung and W. K. Evans: First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol, 5(2), 260-74 (2010)
59. C. Nakanishi and M. Toi: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer, 5(4), 297-309 (2005) (Pubitemid 40488635)
60. D. R. Jones, R. M. Broad, L. D. Comeau, S. J. Parsons and M. W. Mayo: Inhibition of nuclear factor kappaB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation. J Thorac Cardiovasc Surg, 123(2), 310-7 (2002) (Pubitemid 34127119)
61. C. E. Denlinger, B. K. Rundall and D. R. Jones: Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: the role of NF-kappaB. Semin Thorac Cardiovasc Surg, 16(1), 28-39 (2004) (Pubitemid 38714757)
62. H. M. Shen and V. Tergaonkar: NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis, 14(4), 348-63 (2009)
63. M. Karin, Y. Yamamoto and Q. M. Wang: The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov, 3(1), 17-26 (2004) (Pubitemid 38088695)
64. H. Oyaizu, Y. Adachi, T. Okumura, M. Okigaki, N. Oyaizu, S. Taketani, K. Ikebukuro, S. Fukuhara and S. Ikehara: Proteasome inhibitor 1 enhances paclitaxelinduced apoptosis in human lung adenocarcinoma cell line. Oncol Rep, 8(4), 825-9 (2001) (Pubitemid 33758131)
65. J. Voortman, T. P. Resende, M. A. Abou El Hassan, G. Giaccone and F. A. Kruyt: TRAIL therapy in nonsmall cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther, 6(7), 2103-12 (2007) (Pubitemid 47052501)
66. A. M. Davies, P. N. Lara, Jr., P. C. Mack and D. R. Gandara: Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res, 13(15 Pt 2), s4647-51 (2007)
67. T. J. Lynch, D. Fenton, V. Hirsh, D. Bodkin, E. L. Middleman, A. Chiappori, B. Halmos, R. Favis, H. Liu, W. L. Trepicchio, O. Eton and F. A. Shepherd: A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol, 4(8), 1002-9 (2009)
68. G. V. Scagliotti, P. Ceppi, E. Capelletto and S. Novello: Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer, 10 Suppl 1, S35-40 (2009)
69. A. Z. Dudek, K. Lesniewski-Kmak, N. J. Shehadeh, O. N. Pandey, M. Franklin, R. A. Kratzke, E. W. Greeno and P. Kumar: Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer, 100(9), 1379-84 (2009)
70. M. J. Yin, Y. Yamamoto and R. B. Gaynor: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature, 396(6706), 77-80 (1998) (Pubitemid 28520452)
71. K. S. Berman, U. N. Verma, G. Harburg, J. D. Minna, M. H. Cobb and R. B. Gaynor: Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB. Clin Cancer Res, 8(2), 354-60 (2002) (Pubitemid 34193950)
72. S. Shishodia and B. B. Aggarwal: Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res, 64(14), 5004-12 (2004) (Pubitemid 38924549)
73. C. K. Weber, S. Liptay, T. Wirth, G. Adler and R. M. Schmid: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology, 119(5), 1209-18 (2000)
74. J. D. Lay, C. C. Hong, J. S. Huang, Y. Y. Yang, C. Y. Pao, C. H. Liu, Y. P. Lai, G. M. Lai, A. L. Cheng, I. J. Su and S. E. Chuang: Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res, 67(8), 3878-87 (2007)
75. Y. C. Lin, C. T. Shun, M. S. Wu and C. C. Chen: A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factorkappaB. Clin Cancer Res, 12(23), 7165-73 (2006)
76. A. Matsumori, Y. Nunokawa and S. Sasayama: Nifedipine inhibits activation of transcription factor NFkappaB. Life Sci, 67(21), 2655-61 (2000)
77. X. Gao, M. Iwai, S. Inaba, Y. Tomono, H. Kanno, M. Mogi and M. Horiuchi: Attenuation of monocyte chemoattractant protein-1 expression via inhibition of nuclear factor-kappaB activity in inflammatory vascular injury. Am J Hypertens, 20(11), 1170-5 (2007) (Pubitemid 47588824)
78. N. Tomita, K. Yamasaki, K. Izawa, Y. Kunugiza, M. K. Osako, T. Ogihara and R. Morishita: Inhibition of experimental abdominal aortic aneurysm progression by nifedipine. Int J Mol Med, 21(2), 239-44 (2008) (Pubitemid 351222858)
79. B. B. Aggarwal, S. Shishodia, S. K. Sandur, M. K. Pandey and G. Sethi: Inflammation and cancer: how hot is the link? Biochem Pharmacol, 72(11), 1605-21 (2006) (Pubitemid 44666739)
80. Y. Lin, R. Shi, X. Wang and H. M. Shen: Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets, 8(7), 634-46 (2008)
81. D. F. Birt, S. Hendrich and W. Wang: Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther, 90(2-3), 157-77 (2001) (Pubitemid 32913477)
82. S. Y. Wang, R. Feng, Y. Lu, L. Bowman and M. Ding: Inhibitory effect on activator protein-1, nuclear factorkappaB, and cell transformation by extracts of strawberries (Fragaria x ananassa Duch.). J Agric Food Chem, 53(10), 4187-93 (2005) (Pubitemid 40936782)
83. Y. W. Shih, P. S. Chen, C. H. Wu, Y. F. Jeng and C. J. Wang: Alpha-chaconine-reduced metastasis involves a PI3K/Akt signaling pathway with downregulation of NFkappaB in human lung adenocarcinoma A549 cells. J Agric Food Chem, 55(26), 11035-43 (2007)
84. K. Y. Lee, J. S. Park, Y. K. Jee and G. D. Rosen: Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med, 34(6), 462-8 (2002) (Pubitemid 36114364)
85. S. K. Sandur, K. S. Ahn, H. Ichikawa, G. Sethi, S. Shishodia, R. A. Newman and B. B. Aggarwal: Zyflamend, a polyherbal preparation, inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of NF-kappa B activation and NF-kappa B-regulated gene products. Nutr Cancer, 57(1), 78-87 (2007) (Pubitemid 46871572)
86. T. Ikezoe, Y. Yang, T. Saitoh, D. Heber, R. McKenna, H. Taguchi and H. P. Koeffler: PC-SPES down-regulates COX-2 via inhibition of NF-kappaB and C/EBPbeta in non-small cell lung cancer cells. Int J Oncol, 29(2), 453-61 (2006)
87. J. H. Woo, D. Li, K. Wilsbach, H. Orita, J. Coulter, E. Tully, T. K. Kwon, S. Xu and E. Gabrielson: Coix seed extract, a commonly used treatment for cancer in China, inhibits NFkappaB and protein kinase C signaling. Cancer Biol Ther, 6(12), 2005-11 (2007) (Pubitemid 351590416)
88. Y. L. Hsu, P. L. Kuo and C. C. Lin: Proliferative inhibition, cell-cycle dysregulation, and induction ofapoptosis by ursolic acid in human non-small cell lung cancer A549 cells. Life Sci, 75(19), 2303-16 (2004)
89. K. S. Ahn, G. Sethi and B. B. Aggarwal: Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaBregulated antiapoptotic and metastatic gene products. Mol Pharmacol, 71(1), 209-19 (2007) (Pubitemid 46020991)
90. A. A. Shaik, D. L. Hermanson and C. Xing: Identification of methysticin as a potent and non-toxic NFkappa B inhibitor from kava, potentially responsible for kava's chemopreventive activity. Bioorg Med Chem Lett, 19(19), 5732-6 (2009)
91. J. C. Lin, S. C. Yang, T. M. Hong, S. L. Yu, Q. Shi, L. Wei, H. Y. Chen, P. C. Yang and K. H. Lee: Phenanthrenebased tylophorine-1 (PBT-1) inhibits lung cancer cell growth through the Akt and NF-kappaB pathways. J Med Chem, 52(7), 1903-11 (2009)
92. C. Ji, K. R. Kozak and L. J. Marnett: IkappaB kinase, a molecular target for inhibition by 4-hydroxy-2-nonenal. J Biol Chem, 276(21), 18223-8 (2001)
93. S. Shishodia, A. M. Gutierrez, R. Lotan and B. B. Aggarwal: N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Cancer Res, 65(20), 9555-65 (2005) (Pubitemid 41508026)
94. G. Imre, V. Gekeler, A. Leja, T. Beckers and M. Boehm: Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor- 1 down-regulation. Cancer Res, 66(10), 5409-18 (2006) (Pubitemid 43844968)
95. J. Mi, X. Zhang, Y. Liu, S. K. Reddy, Z. N. Rabbani, B. A. Sullenger and B. M. Clary: NF-kappaB inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis. Biochem Biophys Res Commun, 359(3), 475-80 (2007) (Pubitemid 46898974)
96. V. Tergaonkar, M. Pando, O. Vafa, G. Wahl and I. Verma: p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell, 1(5), 493-503 (2002) (Pubitemid 41039129)
97. A. Dey, E. T. Wong, P. Bist, V. Tergaonkar and D. P. Lane: Nutlin-3 inhibits the NFkappaB pathway in a p53- dependent manner: implications in lung cancer therapy. Cell Cycle, 6(17), 2178-85 (2007) (Pubitemid 47450420)
98. T. Marumoto, D. Zhang and H. Saya: Aurora-A - a guardian of poles. Nat Rev Cancer, 5(1), 42-50 (2005) (Pubitemid 40052324)
99. R. D. Carvajal, A. Tse and G. K. Schwartz: Aurora kinases: new targets for cancer therapy. Clin Cancer Res, 12(23), 6869-75 (2006) (Pubitemid 44974478)
100. P. Briassouli, F. Chan, K. Savage, J. S. Reis-Filho and S. Linardopoulos: Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res, 67(4), 1689-95 (2007) (Pubitemid 46383395)
101. Q. Cheng, H. H. Lee, Y. Li, T. P. Parks and G. Cheng: Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Oncogene, 19(42), 4936-40 (2000)
102. Y. Li, F. Ahmed, S. Ali, P. A. Philip, O. Kucuk and F. H. Sarkar: Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res, 65(15), 6934-42 (2005) (Pubitemid 41060733)
103. D. R. Jones, R. M. Broad, L. V. Madrid, A. S. Baldwin, Jr. and M. W. Mayo: Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapyinduced apoptosis. Ann Thorac Surg, 70(3), 930-6; discussion 936-7 (2000)
104. S. Osaki, Y. Nakanishi, K. Takayama, X. H. Pei, H. Ueno and N. Hara: Transfer of IkappaBalpha gene increase the sensitivity of paclitaxel mediated with caspase 3 activation in human lung cancer cell. J Exp Clin Cancer Res, 22(1), 69-75 (2003) (Pubitemid 36396660)
105. S. Sen, H. Sharma and N. Singh: Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun, 331(4), 1245-52 (2005) (Pubitemid 40692490)
106. Q. G. Dong, G. M. Sclabas, S. Fujioka, C. Schmidt, B. Peng, T. Wu, M. S. Tsao, D. B. Evans, J. L. Abbruzzese, T. J. McDonnell and P. J. Chiao: The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene, 21(42), 6510-9 (2002) (Pubitemid 35155455)
107. K. R. Grimes, G. W. Warren, F. Fang, Y. Xu and W. H. St Clair: Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo. Oncol Rep, 16(4), 771-6 (2006)
108. K. R. Grimes, C. Daosukho, Y. Zhao, A. Meigooni and W. St Clair: Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection. Int J Oncol, 27(4), 1047-52 (2005)
109. H. F. Liao, C. D. Kuo, Y. C. Yang, C. P. Lin, H. C. Tai, Y. Y. Chen and Y. J. Chen: Resveratrol enhances radiosensitivity of human non-small cell lung cancer NCIH838 cells accompanied by inhibition of nuclear factor-kappa B activation. J Radiat Res (Tokyo), 46(4), 387-93 (2005)
110. M. Zheng, S. E. Morgan-Lappe, J. Yang, K. M. Bockbrader, D. Pamarthy, D. Thomas, S. W. Fesik and Y. Sun: Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res, 68(18), 7570-8 (2008)
111. V. B. Andela, E. M. Schwarz, J. E. Puzas, R. J. O'Keefe and R. N. Rosier: Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. Cancer Res, 60(23), 6557-62 (2000)
112. T. N. Hartmann, J. A. Burger, A. Glodek, N. Fujii and M. Burger: CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene, 24(27), 4462-71 (2005) (Pubitemid 40961769)
113. J. Ding, J. Li, C. Xue, K. Wu, W. Ouyang, D. Zhang, Y. Yan and C. Huang: Cyclooxygenase-2 induction by arsenite is through a nuclear factor of activated T-celldependent pathway and plays an antiapoptotic role in Beas- 2B cells. J Biol Chem, 281(34), 24405-13 (2006) (Pubitemid 44274213)
114. J. Yang, D. Wei and J. Liu: Repressions of MMP-9 expression and NF-kappa B localization are involved in inhibition of lung carcinoma 95-D cell invasion by (-)- epigallocatechin-3-gallate. Biomed Pharmacother, 59(3), 98-103 (2005) (Pubitemid 40424556)
115. L. H. Wei, K. P. Lai, C. A. Chen, C. H. Cheng, Y. J. Huang, C. H. Chou, M. L. Kuo and C. Y. Hsieh: Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB. Oncogene, 24(3), 390-8 (2005)
116. G. T. Stathopoulos, Z. Zhu, M. B. Everhart, I. Kalomenidis, W. E. Lawson, S. Bilaceroglu, T. E. Peterson, D. Mitchell, F. E. Yull, R. W. Light and T. S. Blackwell: Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol, 34(2), 142-50 (2006) (Pubitemid 43202460)
117. I. Psallidas, S. P. Karabela, C. Moschos, T. P. Sherrill, A. Kollintza, S. Magkouta, P. Theodoropoulou, C. Roussos, T. S. Blackwell, I. Kalomenidis and G. T. Stathopoulos: Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study. Mol Cancer, 9, 56 (2010)
118. R. L. Keith: Chemoprevention of lung cancer. Proc Am Thorac Soc, 6(2), 187-93 (2009)
119. J. Cuzick, F. Otto, J. A. Baron, P. H. Brown, J. Burn, P. Greenwald, J. Jankowski, C. La Vecchia, F. Meyskens, H. J. Senn and M. Thun: Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol, 10(5), 501-7 (2009)
120. N. Khan, F. Afaq, M. H. Kweon, K. Kim and H. Mukhtar: Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res, 67(7), 3475-82 (2007) (Pubitemid 46724889)
121. N. Khan, N. Hadi, F. Afaq, D. N. Syed, M. H. Kweon and H. Mukhtar: Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis, 28(1), 163-73 (2007) (Pubitemid 44942640)
122. M. Karin: Nuclear factor-kappaB in cancer development and progression. Nature, 441(7092), 431-6 (2006) (Pubitemid 44050137)
123. S. S. Hecht, F. Kassie and D. K. Hatsukami: Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers. Nat Rev Cancer, 9(7), 476-88 (2009)
124. G. L. Russo: Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol, 74(4), 533-44 (2007) (Pubitemid 47042006)
125. S. Vallabhapurapu and M. Karin: Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol, 27, 693-733 (2009)
126. L. Zitvogel, L. Apetoh, F. Ghiringhelli and G. Kroemer: Immunological aspects of cancer chemotherapy. Nat Rev Immunol, 8(1), 59-73 (2008)
127. V. Baud and M. Karin: Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov, 8(1), 33-40 (2009)
128. A. Nencioni, F. Grunebach, F. Patrone, A. Ballestrero and P. Brossart: Proteasome inhibitors: antitumor effects and beyond. Leukemia, 21(1), 30-6 (2007) (Pubitemid 44921831)
129. G. Ayala, J. Yan, R. Li, Y. Ding, T. C. Thompson, M. P. Mims, T. G. Hayes, V. MacDonnell, R. G. Lynch, A. Frolov, B. J. Miles, T. M. Wheeler, J. W. Harper, M. J. Tsai, M. M. Ittmann and D. Kadmon: Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res, 14(22), 7511-8 (2008)
130. C. Aguilera, R. Hoya-Arias, G. Haegeman, L. Espinosa and A. Bigas: Recruitment of IkappaBalpha to the hes1 promoter is associated with transcriptional repression. Proc Natl Acad Sci U S A, 101(47), 16537-42 (2004) (Pubitemid 39557748)